Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment. Take 2 mins to learn more.

News & Insights

SpyBiotech receives grant from the Bill & Melinda Gates Foundation to advance novel SpyVector Platform.

  • SpyBiotech has received a grant of $4m from the Bill & Melinda Gates Foundation to further develop its novel vaccine technology.
  • This project will harness SpyBio’s ‘plug and display’ technology to design a broadly cross-protective coronavirus vaccine.

SpyBiotech has receieved funding to further develop it ‘plug and display’ SpyVector platform to design an broadly cross-protective coronavirus vaccine.

Spybiotech are developing a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases. While the Company continues to develop the SpyVector platform, it is advancing its lead candidate – a vaccine targeting human cytomegalovirus (HCMV) using its Hepatitis B virus-like-particle platform technology – into the clinic later this year.

Sumi Biswas, Ph.D., President and CSO of SpyBio said: “This grant will showcase the potential of the SpyVector technology which can be applied to generate vaccines against a wide range of pathogens and therapeutic applications. Our SpyVector technology, developed by our Principal Scientist Dr. Matthew Dicks and his team, has the potential to generate more broadly protective coronavirus vaccines.”

Read the full press release here.